Compare Smith & Nephew plc (SNN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Veritone Inc — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Smith & Nephew plc is far larger — about 186.7× Veritone Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Veritone Inc for 12 Days on average.
| SNN | VERI | |
|---|---|---|
Market Cap | $11.10B | $59.46M |
Volume | 1,051,703 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $37.17 | $8.39 |
52-Week Low | $26.42 | $0.56 |
Typical Hold Time | 121 Days | 12 Days |
Enterprise Value | $14.13B | $94.86M |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Veritone (VERI) trades at $0.5851, down 15.36% in the past 24 hours, reflecting significant bearish pressure. The company shows concerning fundamentals with a net income margin of -117.54% and negative ROE of -547.67% for 2025, though it maintains a gross margin of 66.2%. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, while facing securities class action investigations. Technical indicators show mixed signals with bearish moving averages but bullish oscillators.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests upside potential with a $3.75 price target. Key risks include ongoing legal scrutiny, execution challenges in achieving profitability, and competitive pressures in the AI solutions space. The stock presents high-risk speculative potential for investors betting on turnaround execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
